E154 Whole team approach to connective tissue disease and vasculitis (CTDVAS): a survey study of healthcare professional perceptions of a weekly multidisciplinary team meeting

Abstract Background/Aims Connective tissue diseases and systemic vasculitis can be organ and life-threatening. British Society for Rheumatology 2025 ANCA-associated vasculitis recommendations highlight the need for coordinated multi-specialty care and timely access to definitive intravenous therapy. The Bristol Royal Infirmary (BRI) weekly virtual CTDVAS MDT includes all consultants, residents, nursing and admins. MDT is open to all specialties. This survey explores healthcare professionals’ perspectives. Methods An anonymous online survey was circulated via email to participants of the CTDVAS meeting. A 10-item questionnaire included questions on role and specialty. Participants were then asked to respond to their agreement or disagreement with statements about the CTDVAS MDT in terms of supporting management of complex patients, educational value, and initiation of targeted therapies using a 5-point Likert response. Results were analysed descriptively. Results Survey conducted across August-September 2025. Respondents (n = 25): Consultants (56%), Residents/fellow (36%), Nurses (8%). Specialties: Rheumatology (72%), Haematology (8%), Respiratory (8%), Cardiology (8%), Dermatology (4%). Twenty-three (92%) of the respondents strongly agreed or agreed with the statements that the CTDVAS MDT: helped to improve diagnostic clarity; contributed effectively to management planning; provided educational value; enhanced communication and collaboration within the rheumatology team and with other specialities; and supported professional development, knowledge and expertise in CTDVAS. Two of the respondents were neutral on these statements. Twenty-four (96%) of the 25 respondents strongly agreed/agreed that the MDT meant they can: discuss their urgent patients in timely way; discuss patients they are worried about; contribute to the discussions about complex patients. Twenty-one (84%) agreed that the MDT is an enjoyable part of their weekly schedule. Respondents were also asked about the MDT’s helpfulness in timely initiation of treatment. Results are summarised in Table 1. Finally, open-ended feedback from respondents revealed the following insights: Shares clinical responsibility for clinicians and often provides a definitive management plan for complex cases. Clear evidence of better outcomes for patients, even those with an initial very poor prognosis. Conclusion The CTDVAS virtual weekly MDT was perceived as an effective platform for facilitating complex decision-making, initiation of definitive immunosuppression in a timely way and strengthening collaboration across specialties in a supportive environment. Disclosure U. Kulasinghe: None. E. Perry: None. E. Davies: None. T. Reynolds: None. K. Austin: None. R. Marshall: None. B. Boyce: None. M. Roy: None. E. Reilly: None. A. Ferreira: None. D. Walewska: None. J. Robson: None.